Aura Biosciences (AURA)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	26.18 mm	26.18 mm	26.18 mm	26.18 mm	26.18 mm	26.18 mm
Cash burn (monthly)	1.56 mm	2.52 mm	7.74 mm	7.76 mm	5.09 mm	6.10 mm
Cash used (since last report)	6.26 mm	10.13 mm	31.16 mm	31.22 mm	20.49 mm	24.56 mm
Cash remaining	19.91 mm	16.05 mm	-4.99 mm	-5.04 mm	5.69 mm	1.61 mm
Runway (months of cash)	12.8	6.4	-0.6	-0.7	1.1	0.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

AURA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	88	79	+11.4%
Opened positions	13	13	–
Closed positions	4	15	-73.3%
Increased positions	30	33	-9.1%
Reduced positions	25	20	+25.0%

13F shares	Current	Prev Q	Change
Total value	323.47 bn	294.91 bn	+9.7%
Total shares	51.29 mm	49.43 mm	+3.8%
Total puts	38.50 k	1.80 k	+2038.9%
Total calls	122.00 k	800.00	+15150.0%
Total put/call ratio	0.3	2.3	-86.0%

Largest owners	Shares	Value	Change
Matrix Capital Management	6.92 mm	$61.68 bn	0.0%
Eventide Asset Managment	5.80 mm	$51.70 bn	0.0%
Adage Capital Partners GP, L.L.C.	4.88 mm	$43.49 bn	-0.1%
Adage Capital Management	4.88 mm	$50.57 mm	NEW
BlackRock	3.16 mm	$28.16 bn	NEW
Medicxi Growth I	3.04 mm	$52.32 mm	0.0%
Medicxi Ventures Management	3.04 mm	$27.09 bn	0.0%
Advent Life Sciences	2.02 mm	$0.00	0.0%
Vanguard	1.81 mm	$16.09 bn	+2.2%
Lundbeckfond Invest A/S	1.75 mm	$18.13 mm	-13.3%

Largest transactions	Shares	Bought/sold	Change
Adage Capital Management	4.88 mm	+4.88 mm	NEW
BlackRock	3.16 mm	+3.16 mm	NEW
BLK BlackRock	0.00	-3.01 mm	EXIT
Citadel Advisors	1.01 k	-2.34 mm	-100.0%
GS The Goldman Sachs Group, Inc.	113.97 k	-915.95 k	-88.9%
Lundbeckfond Invest A/S	1.75 mm	-267.54 k	-13.3%
BEN Franklin Resources	1.67 mm	+215.60 k	+14.8%
ADAR1 Capital Management	73.66 k	-129.57 k	-63.8%
FMR	101.22 k	-129.23 k	-56.1%
Wellington Management	116.39 k	+116.39 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

AURA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
21 Jan 25	Amy Elazzouzi	Common Stock	Sell	Dispose S	No	No	7.6715	1,001	7.68 k	38,442
21 Jan 25	los Pinos Elisabet de	Common Stock	Sell	Dispose S	No	No	7.6704	15,955	122.38 k	304,692
18 Nov 24	Janet Jill Hopkins	Common Stock	Sell	Dispose S	No	No	9.3608	11,822	110.66 k	151,693
29 Oct 24	Amy Elazzouzi	Common Stock	Sell	Dispose S	No	No	10.7385	553	5.94 k	39,443
29 Oct 24	los Pinos Elisabet de	Common Stock	Sell	Dispose S	No	No	10.7378	9,200	98.79 k	320,647

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Why Check-Cap Shares Are Trading Higher By Over 52%; Here Are 20 Stocks Moving Premarket

3 Jan 25

HC Wainwright & Co. Reiterates Buy on Aura Biosciences, Maintains $22 Price Target

14 Nov 24

HC Wainwright & Co. analyst Edward White reiterates Aura Biosciences (NASDAQ:AURA) with a Buy and maintains $22 price target.

Aura Biosciences Q3 EPS $(0.42) Beats $(0.45) Estimate

12 Nov 24

Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.45) by 6.67 percent. This is a 12.5 percent increase over losses of $(0.48) per share from